Published on January 20th, 2015 | by ddeupree0
CSR – Central serous retinopathy
Central serous retinopathy (CSR) is an eye disorder that is found most commonly in young men, 20 to 50 years of age.
Symptoms of CSR usually include a rather sudden onset of blurred vision in one eye, minification of images, reduced color vision, or a central “blind spot” in the involved eye.
The exact cause of the condition is unknown, but the disorder is characterized by “leakage” of fluid in the central macula (see illustration). Patients with CSR, also called central serous choroidopathy (CSCR), generally have vision in the 20/20 to 20/100 range and a serous (clear fluid) retinal detachment may be discovered by the examining ophthalmologist. A fluorescein angiogram may be used to confirm the diagnosis. Type A personalities and systemic hypertension may be associated with CSR.
Patients diagnosed with CSR generally have a good prognosis for recovery of vision, though the condition may take six months or more to resolve. Recurrence of leakage is quite common.
Treatment for central serous retinopathy
Retinal laser treatment has been around for decades. Conventional laser treatment is often effective but can result in tissue burns and permanent and sometimes progressive scarring that can cause vision loss. What sets MicroPulse technology apart is that it reduces or eliminates treatment risk with less patient discomfort, and therefore can be repeated as needed without harm to the patient’s vision.
The new MicroPulse laser technology works by segmenting the laser emissions into spaced, repetitive “micropulses”. This allows for finer surgeon control and lower energy output — greatly reducing heat-damaging effects on the retinal tissue. This lower energy, fragmented approach creates superior outcomes.
Conventional laser treatment
Laser photocoagulation (treatment) to the retina may speed recovery of vision, but does not always result in better final visual acuity. Laser photocoagulation itself has some small risks, which require careful consideration.
Most patients are followed every two to three months until the condition spontaneously improves. If significant visual loss persists beyond 4-6 months, laser treatment may again be considered.